Clinical Lab Products: Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.0.82″ background_layout=”light” border_style=”solid” box_shadow_position=”outer”]
Biodesix’s primary immunotherapy resistance test demonstrated utility in classifying NSCLC patients treated with nivolumab by overall survival. The test classification is independent of PD-L1 status.
“Anti-PD-1 therapy is capable of restoring immunity and has greatly increased overall survival rates for patients. However, we know that this therapy does not benefit everyone,” says Egbert Smit, MD, PhD, a pulmonary oncologist at the Netherlands Cancer Institute and lead author of the study. “A test that can determine which patients will respond poorly to immunotherapy would greatly optimize treatment regimens.”